HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

beta- naphthylsulfonyl- R- (d- Pip)- Ada- Abu- DYEPIPEEA- (Cha)- (d- Glu)- OH- AcOH (P551)

a potent synthetic bifunctional thrombin inhibitor based on hirudin sequence

Also Known As:

P551; P 551; P-551

Networked: 6 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Serpins: 906
    - Antithrombin Proteins: 6
      - Hirudins: 707
        beta-naphthylsulfonyl-R-(d-Pip)-Ada-Abu-DYEPIPEEA-(Cha)-(d-Glu)-OH-AcOH: 6
- Peptides: 82426
  - Serpins: 906
    - Antithrombin Proteins: 6
      - Hirudins: 707
        beta-naphthylsulfonyl-R-(d-Pip)-Ada-Abu-DYEPIPEEA-(Cha)-(d-Glu)-OH-AcOH: 6

Experts

1.	Arjomandi, Hamid: 1 article (01/2017)
2.	Chen, Jun: 1 article (01/2017)
3.	Ehman, Richard L: 1 article (01/2017)
4.	Glaser, Kevin J: 1 article (01/2017)
5.	Lewis, Sean: 1 article (01/2017)
6.	Miette, Véronique: 1 article (01/2017)
7.	Oudry, Jennifer: 1 article (01/2017)
8.	Rosenfeld, Richard: 1 article (01/2017)
9.	Sandrin, Laurent: 1 article (01/2017)
10.	Smyrk, Thomas C: 1 article (01/2017)

Related Diseases

1.	Wounds and Injuries (Trauma) 08/01/2013 - "Mean Injury Severity Scores and Revised Trauma Scores were similar (P = .484, P = .551) between the open repair group (n = 36) and the endovascular repair group (n = 14). " 01/01/2017 - "Five studies had data suitable for comparative meta-analysis, which showed no differences by closure technique for treatment success (P = .480), overall complications (P = .551), need for revision surgery (P = .624), or the incidence of subcutaneous emphysema or pneumothorax (P = .512), urgent airway problems (P = .126), wound infection (P = 1.00), or wound dehiscence or fistula (P = .818). "
2.	Wound Infection (Wound Infections) 01/01/2017 - "Five studies had data suitable for comparative meta-analysis, which showed no differences by closure technique for treatment success (P = .480), overall complications (P = .551), need for revision surgery (P = .624), or the incidence of subcutaneous emphysema or pneumothorax (P = .512), urgent airway problems (P = .126), wound infection (P = 1.00), or wound dehiscence or fistula (P = .818). "
3.	Subcutaneous Emphysema 01/01/2017 - "Five studies had data suitable for comparative meta-analysis, which showed no differences by closure technique for treatment success (P = .480), overall complications (P = .551), need for revision surgery (P = .624), or the incidence of subcutaneous emphysema or pneumothorax (P = .512), urgent airway problems (P = .126), wound infection (P = 1.00), or wound dehiscence or fistula (P = .818). "
4.	Pneumothorax 01/01/2017 - "Five studies had data suitable for comparative meta-analysis, which showed no differences by closure technique for treatment success (P = .480), overall complications (P = .551), need for revision surgery (P = .624), or the incidence of subcutaneous emphysema or pneumothorax (P = .512), urgent airway problems (P = .126), wound infection (P = 1.00), or wound dehiscence or fistula (P = .818). "
5.	Fistula 01/01/2017 - "Five studies had data suitable for comparative meta-analysis, which showed no differences by closure technique for treatment success (P = .480), overall complications (P = .551), need for revision surgery (P = .624), or the incidence of subcutaneous emphysema or pneumothorax (P = .512), urgent airway problems (P = .126), wound infection (P = 1.00), or wound dehiscence or fistula (P = .818). "

Related Drugs and Biologics

1.	Thrombin
2.	Hirudins
3.	Helium
4.	Fibrinolytic Agents (Antithrombotic Agents)
5.	beta- naphthylsulfonyl- (d- Pip)- Ada- Abu- DFEEIPEEYLQ- OH- AcOH (P 532)

Related Therapies and Procedures

1.	Reoperation
2.	Length of Stay
3.	Lasers (Laser)